Mark Heinen

Insider Reports History

Reporting-owner location: San Francisco, CA
Latest reporting-owner signature: /s/Mark Heinen
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Mark Heinen

Form 4 holding Chief Financial Officer

Volato Group, Inc.

Security class: Common Stock
Shares / value: 60,919
Estimated value: $110,972
Report date: 27 Mar 2026
Price: $0.7500
Ownership: Direct

Form 4 holding Chief Financial Officer

Better Therapeutics, Inc.

Security class: Common Stock
Shares / value: 139,723
Estimated value: $23,739
Report date: 05 Apr 2023
Price: $0.1699
Ownership: Direct

Form 4 holding Chief Financial Officer

Better Therapeutics, Inc.

Security class: Common Stock
Shares / value: 2,281
Estimated value: $387
Report date: 01 Mar 2023
Price: $0.1699
Ownership: By daughter

Form 4 holding Chief Financial Officer

Volato Group, Inc.

Security class: Performance-Based Restricted Stock Unit
Shares / value: 47,840
Estimated value
Report date: 07 Jun 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Chief Financial Officer

Better Therapeutics, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 28,550
Estimated value
Report date: 01 Mar 2023
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Mark Heinen

4 SOAR

Volato Group, Inc.

Report period: 27 Mar 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 31 Mar 2026, 08:07
Role: Chief Financial Officer
Next action: Open filing details

4 SOAR

Volato Group, Inc.

Report period: 07 May 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 09 May 2025, 17:10
Role: Chief Financial Officer
Next action: Open filing details

4 SOAR

Volato Group, Inc.

Report period: 07 Jun 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 11 Jun 2024, 18:48
Role: Chief Financial Officer
Next action: Open filing details

4 SOAR

Volato Group, Inc.

Report period: 06 Jun 2024
Transactions: 1
Transaction value: +$6,800
Accepted by SEC: 10 Jun 2024, 18:15
Role: Chief Financial Officer
Next action: Open filing details

3 SOAR

Volato Group, Inc.

Report period: 01 Dec 2023
Transactions: 0
Transaction value: $0
Accepted by SEC: 19 Dec 2023, 16:05
Role: Chief Financial Officer
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 01 Mar 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 21 Apr 2023, 18:14
Role: Chief Financial Officer
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 30 Nov 2022
Transactions: 1
Transaction value: +$19,512
Accepted by SEC: 02 Dec 2022, 15:15
Role: Head of Finance and Interim Chief Financial Officer
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 12 Sep 2022
Transactions: 2
Transaction value: +$97,000
Accepted by SEC: 14 Sep 2022, 16:37
Role: Head of Finance and Interim Chief Financial Officer
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 24 Jun 2022
Transactions: 1
Transaction value: +$4,000
Accepted by SEC: 28 Jun 2022, 16:24
Role: Head of Finance and interim Chief Financial Officer
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 10 Jun 2022
Transactions: 1
Transaction value: +$7,800
Accepted by SEC: 10 Jun 2022, 18:23
Role: Head of Finance and interim Chief Financial Officer
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 31 Mar 2022
Transactions: 2
Transaction value: +$9,900
Accepted by SEC: 04 Apr 2022, 16:28
Role: Head of Finance and interim Chief Financial Officer
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 13 Dec 2021
Transactions: 3
Transaction value: +$16,400
Accepted by SEC: 15 Dec 2021, 15:53
Role: Head of Finance and interim Chief Financial Officer
Next action: Open filing details

4

Better Therapeutics, Inc.

Report period: 28 Oct 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 01 Nov 2021, 20:47
Role: Head of Finance and interim Chief Financial Officer
Next action: Open filing details

3

Better Therapeutics, Inc.

Report period: 28 Oct 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 01 Nov 2021, 20:35
Role: Head of Finance and interim Chief Financial Officer Exhibit 24 - Power of Attorney
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .